Pharmacological Overview of the BGP-15 Chemical Agent as a New Drug Candidate for the Treatment of Symptoms of Metabolic Syndrome

Pharmacological Overview of the BGP-15 Chemical Agent as a New Drug Candidate for the Treatment of Symptoms of Metabolic Syndrome

BGP-15 is a new insulin sensitizer drug candidate, which was developed by Hungarian researchers. In recent years, numerous research groups have studied its beneficial effects. It is effective in the treatment of insulin resistance and it has protective effects in Duchenne muscular dystrophy, diastol...

Full description

Bibliographic Details
Main Authors: Ágota Pető, Dóra Kósa, Pálma Fehér, Zoltán Ujhelyi, Dávid Sinka, Miklós Vecsernyés, Zoltán Szilvássy, Béla Juhász, Zoltán Csanádi, László Vígh, Ildikó Bácskay
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Molecules
Subjects:
bgp-15
chaperone co-inducer
parp inhibitor
insulin sensitizer
Online Access:https://www.mdpi.com/1420-3049/25/2/429

Internet

https://www.mdpi.com/1420-3049/25/2/429

Similar Items